Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ABL1 | P00519 | 12/20 | 0.52 |
| ▸ | BCR | P11274 | 11/20 | 0.52 |
| ▸ | PRKCA | P17252 | 5/20 | 0.52 |
| ▸ | EGFR | P00533 | 5/20 | 0.52 |
| ▸ | SRC | P12931 | 1/20 | 0.52 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.51 |
| ▸ | PDGFRB | P09619 | 5/20 | 0.50 |
| ▸ | PDGFRA | P16234 | 5/20 | 0.50 |
| ▸ | PLK1 | P53350 | 1/20 | 0.48 |
| ▸ | JAK3 | P52333 | 1/20 | 0.47 |
| ▸ | BTK | Q06187 | 1/20 | 0.47 |
| ▸ | ITK | Q08881 | 1/20 | 0.47 |
| ▸ | GAA | P10253 | 1/20 | 0.45 |
| ▸ | PIK3CA | P42336 | 1/20 | 0.44 |
| ▸ | PIK3CB | P42338 | 1/20 | 0.44 |
| ▸ | PIK3CG | P48736 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3107998 | 0.90 | ABL1 (0.53) | ABL1BCRPRKCAEGFRSRC | |
| SCHEMBL14021195 | 0.88 | ABL1 (0.52) | ABL1BCRPRKCAEGFRSRC | |
| SCHEMBL31671097 | 0.88 | ABL1 (0.52) | ABL1BCRPRKCAEGFRSRC | |
| SCHEMBL3097563 | 0.88 | ABL1 (0.52) | ABL1BCRPRKCAEGFRSRC | |
| SCHEMBL2572266 | 0.87 | ABL1 (0.55) | ABL1BCRPRKCAEGFRSRC | |
| SCHEMBL29364396 | 0.86 | ABL1 (0.69) | ABL1BCRPRKCAEGFRSRC | |
| SCHEMBL1550 | 0.86 | ABL1 (0.69) | ABL1BCRPRKCAEGFRSRC | |
| SCHEMBL3093785 | 0.86 | PIK3CA (0.55) | ABL1BCRPRKCAEGFRSRC | |
| Water SCHEMBL28827802 | 0.85 | ABL1 (0.68) | ABL1BCRPRKCAEGFRSRC | |
| SCHEMBL2573788 | 0.85 | ABL1 (0.65) | ABL1BCRPRKCAEGFRSRC |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8338417-B2 | Compounds and compositions as c-kit and PDGFR kinase inhibitors | IRM LLC (BM) | 2012-12-25 | — | — | US | disclosed |
| US-8338417-B2 | Compounds and compositions as c-kit and PDGFR kinase inhibitors | IRM LLC (BM) | 2012-12-25 | — | — | US | disclosed |
| US-20100234406-A1 | COMPOUNDS AND COMPOSITIONS AS C-KIT AND PDGFR KINASE INHIBITORS | IRM LLC (BM) | 2010-09-16 | — | — | US | disclosed |
| US-20100234406-A1 | COMPOUNDS AND COMPOSITIONS AS C-KIT AND PDGFR KINASE INHIBITORS | IRM LLC (BM) | 2010-09-16 | — | — | US | disclosed |
| US-20100048539-A1 | COMPOUNDS AND COMPOSITIONS AS PROTEIN KINASE INHIBITORS | IRM LLC (BM) | 2010-02-25 | — | — | US | disclosed |
| US-20100048539-A1 | COMPOUNDS AND COMPOSITIONS AS PROTEIN KINASE INHIBITORS | IRM LLC (BM) | 2010-02-25 | — | — | US | disclosed |
| US-20100048539-A1 | COMPOUNDS AND COMPOSITIONS AS PROTEIN KINASE INHIBITORS | IRM LLC (BM) | 2010-02-25 | — | — | US | disclosed |
| CN-101622244-A | Compounds and compositions as protein kinase inhibitors | IRM LLC | 2010-01-06 | — | — | CN | disclosed |
| EP-2079729-A1 | COMPOUNDS AND COMPOSITIONS AS PROTEIN KINASE INHIBITORS | IRM LLC (BM) | 2009-07-22 | — | — | EP | disclosed |
| WO-2008137794-A1 | COMPOUNDS AND COMPOSITIONS AS C-KIT AND PDGFR KINASE INHIBITORS | IRM LLC (BM) | 2008-11-13 | — | — | WO | disclosed |
| WO-2008058037-A1 | COMPOUNDS AND COMPOSITIONS AS PROTEIN KINASE INHIBITORS | IRM LLC (BM) | 2008-05-15 | — | — | WO | disclosed |
| WO-2008058037-A1 | COMPOUNDS AND COMPOSITIONS AS PROTEIN KINASE INHIBITORS | IRM LLC (BM) | 2008-05-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100048539-A1 | COMPOUNDS AND COMPOSITIONS AS PROTEIN KINASE INHIBITORS | PDGFRB, PDGFRA, KIT | ABL1 9/4885BCR 65/4885PRKCA 4/4885 |
| US-20100234406-A1 | COMPOUNDS AND COMPOSITIONS AS C-KIT AND PDGFR KINASE INHIBITORS | KIT, PDGFRA, PDGFRB | ABL1 10/4885BCR 95/4885PRKCA 6/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.